Compare Stocks: NVNO, BEAT, HSCS, and LFWD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAT HeartBeam	$0.42 +14.3%	$0.47	$0.36 ▼ $4.00	$23.61M	-0.8	977,463 shs	1.72 million shs
HSCS HeartSciences	$3.89 -6.9%	$3.11	$1.63 ▼ $5.25	$18.83M	1.85	800,810 shs	134,308 shs
LFWD Lifeward	$6.03 -8.6%	$7.23	$4.14 ▼ $10.20	$17.07M	0.39	14,569 shs	11,916 shs
NVNO enVVeno Medical	$8.17 +4.7%	$10.34	$7.01 ▼ $35.17	$5.63M	1.06	18,414 shs	25,183 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAT HeartBeam	-0.35%	-5.73%	-22.00%	-49.08%	-77.85%
HSCS HeartSciences	+3.21%	-7.52%	+32.70%	+49.82%	+20.11%
LFWD Lifeward	-3.05%	-5.31%	-12.43%	-16.47%	-21.55%
NVNO enVVeno Medical	-8.56%	-12.95%	-32.00%	-30.67%	-75.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAT HeartBeam	$0.42 +14.3%	$0.47	$0.36 ▼ $4.00	$23.61M	-0.8	977,463 shs	1.72 million shs
HSCS HeartSciences	$3.89 -6.9%	$3.11	$1.63 ▼ $5.25	$18.83M	1.85	800,810 shs	134,308 shs
LFWD Lifeward	$6.03 -8.6%	$7.23	$4.14 ▼ $10.20	$17.07M	0.39	14,569 shs	11,916 shs
NVNO enVVeno Medical	$8.17 +4.7%	$10.34	$7.01 ▼ $35.17	$5.63M	1.06	18,414 shs	25,183 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAT HeartBeam	-0.35%	-5.73%	-22.00%	-49.08%	-77.85%
HSCS HeartSciences	+3.21%	-7.52%	+32.70%	+49.82%	+20.11%
LFWD Lifeward	-3.05%	-5.31%	-12.43%	-16.47%	-21.55%
NVNO enVVeno Medical	-8.56%	-12.95%	-32.00%	-30.67%	-75.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAT HeartBeam	2.56	Moderate Buy	$4.00	854.65% Upside
HSCS HeartSciences	2.00	Hold	$8.00	105.66% Upside
LFWD Lifeward	2.25	Hold	$10.00	65.84% Upside
NVNO enVVeno Medical	2.33	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVNO, BEAT, HSCS, and LFWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	BEAT HeartBeam	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/25/2026	NVNO enVVeno Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/24/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/22/2026	BEAT HeartBeam	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/21/2026	HSCS HeartSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/2/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	LFWD Lifeward	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2026	LFWD Lifeward	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/18/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	LFWD Lifeward	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/27/2026	LFWD Lifeward	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAT HeartBeam	N/A	N/A	N/A	N/A	$0.06 per share	N/A
HSCS HeartSciences	N/A	N/A	N/A	N/A	($0.42) per share	N/A
LFWD Lifeward	$22.03M	0.77	N/A	N/A	$5.52 per share	1.09
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	$41.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAT HeartBeam	-$21.01M	-$0.51	N/A	N/A	N/A	N/A	-686.78%	-348.65%	11/12/2026 (Estimated)
HSCS HeartSciences	-$9.14M	-$3.22	N/A	N/A	N/A	N/A	-816.90%	-181.97%	N/A
LFWD Lifeward	-$19.91M	-$16.82	N/A	N/A	N/A	-141.28%	-235.86%	-81.72%	11/13/2026 (Estimated)
NVNO enVVeno Medical	-$19.47M	-$19.33	N/A	N/A	N/A	N/A	-62.28%	-56.83%	10/30/2026 (Estimated)

Latest NVNO, BEAT, HSCS, and LFWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/14/2026	Q1 2027	HSCS HeartSciences	-$0.72	-$0.86	-$0.14	-$0.86	$0.10 million	$0.00 million
8/15/2026	Q2 2026	LFWD Lifeward	-$1.39	-$1.46	-$0.07	-$4.12	$6.53 million	$6.62 million
8/13/2026	Q2 2026	BEAT HeartBeam	-$0.0860	-$0.10	-$0.0140	-$0.10	$0.15 million	N/A
7/30/2026	Q2 2026	NVNO enVVeno Medical	-$4.69	-$5.37	-$0.68	-$5.37	$1.00 million	N/A
7/23/2026	Q4 2026	HSCS HeartSciences	-$0.66	-$0.88	-$0.22	-$0.87	$0.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAT HeartBeam	N/A	N/A	N/A	N/A	N/A
HSCS HeartSciences	N/A	N/A	N/A	N/A	N/A
LFWD Lifeward	N/A	N/A	N/A	N/A	N/A
NVNO enVVeno Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAT HeartBeam	N/A	3.66	3.61
HSCS HeartSciences	N/A	0.14	0.07
LFWD Lifeward	0.70	2.33	1.77
NVNO enVVeno Medical	N/A	11.70	11.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAT HeartBeam	7.77%
HSCS HeartSciences	17.24%
LFWD Lifeward	26.76%
NVNO enVVeno Medical	34.71%

Insider Ownership

Company	Insider Ownership
BEAT HeartBeam	17.95%
HSCS HeartSciences	4.90%
LFWD Lifeward	1.50%
NVNO enVVeno Medical	15.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAT HeartBeam	1,700	56.35 million	46.23 million	Not Optionable
HSCS HeartSciences	14	4.84 million	4.61 million	Not Optionable
LFWD Lifeward	81	2.83 million	2.79 million	Optionable
NVNO enVVeno Medical	33	690,000	591,000	No Data

NVNO, BEAT, HSCS, and LFWD Headlines

Recent News About These Companies

enVVeno Medical Corporation: enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series

September 16, 2026 | finanznachrichten.de

enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series

September 16, 2026 | finance.yahoo.com

enVVeno Medical Corporation: enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

September 11, 2026 | finanznachrichten.de

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

September 11, 2026 | accessnewswire.comA

enVVeno Medical Participates in the Virtual Investor ‘Why Now’ On-Demand Conference

August 29, 2026 | palmbeachpost.comP

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

August 27, 2026 | finance.yahoo.com

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

August 27, 2026 | accessnewswire.comA

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to ...

August 4, 2026 | finance.yahoo.com

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments

August 4, 2026 | accessnewswire.comA

enVVeno Medical Corporation: enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement ...

July 31, 2026 | finanznachrichten.de

enVVeno Medical wins FDA IDE for non-surgical transcatheter replacement venous valve

July 31, 2026 | massdevice.com

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

July 31, 2026 | accessnewswire.comA

enVVeno Medical Corp.

July 16, 2026 | barrons.com

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor “What This Means” Segment

July 15, 2026 | oklahoman.comO

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

July 15, 2026 | accessnewswire.comA

enVVeno Medical Updates Investors With New Presentation

July 15, 2026 | tipranks.com

enVVeno Medical Corporation: enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

July 7, 2026 | finanznachrichten.de

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

July 7, 2026 | accessnewswire.comA

enVVeno Medical Earnings Estimates, EPS & Revenue | NASDAQ:NVNO

June 25, 2026 | benzinga.com

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series

June 22, 2026 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVNO, BEAT, HSCS, and LFWD Company Descriptions

HeartBeam NASDAQ:BEAT

$0.42 +0.05 (+14.29%)

Closing price 04:00 PM Eastern

Extended Trading

$0.44 +0.02 (+4.06%)

As of 04:21 PM Eastern

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

HeartSciences NASDAQ:HSCS

$3.89 -0.29 (-6.94%)

Closing price 04:00 PM Eastern

Extended Trading

$3.92 +0.02 (+0.64%)

As of 04:10 PM Eastern

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Lifeward NASDAQ:LFWD

$6.03 -0.57 (-8.64%)

Closing price 03:59 PM Eastern

Extended Trading

$6.03 0.00 (0.00%)

As of 04:10 PM Eastern

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.

enVVeno Medical NASDAQ:NVNO

$8.16 +0.37 (+4.68%)

Closing price 03:58 PM Eastern

Extended Trading

$8.86 +0.70 (+8.57%)

As of 04:10 PM Eastern

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVNO, BEAT, HSCS, and LFWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVNO, BEAT, HSCS, and LFWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVNO, BEAT, HSCS, and LFWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVNO, BEAT, HSCS, and LFWD Company Descriptions

HeartBeam NASDAQ:BEAT

HeartSciences NASDAQ:HSCS

Lifeward NASDAQ:LFWD

enVVeno Medical NASDAQ:NVNO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVNO, BEAT, HSCS, and LFWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVNO, BEAT, HSCS, and LFWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVNO, BEAT, HSCS, and LFWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVNO, BEAT, HSCS, and LFWD Company Descriptions

HeartBeam NASDAQ:BEAT

HeartSciences NASDAQ:HSCS

Lifeward NASDAQ:LFWD

enVVeno Medical NASDAQ:NVNO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools